Info

🌱 來自：double_hit_and_double_expressors_in_lymphoma

polarix

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304

1. • Design: Phase 3, double-blind, placebo-controlled, international trial
2. • Number of patients: 879 patients
3. • Patients characteristics: Patients with previously untreated intermediate-risk or high-risk DLBCL, aged 18 to 80 years
4. • Agent:
   • Intervention group: Polatuzumab vedotin in place of vincristine in R-CHOP
   • Control group: Standard R-CHOP
5. • Treatment line: Previously untreated
6. • Trial Acronym (NCTId Number): NCT03274492
7. • Comparison of outcomes:

Outcome	Pola-R-CHP Group	R-CHOP Group
Progression-free survival	76.7% (95% CI, 72.7 to 80.8)	70.2% (95% CI, 65.8 to 74.6)
Overall survival	88.7% (95% CI, 85.7 to 91.6)	88.6% (95% CI, 85.6 to 91.6)
Response rate	not reported	not reported

: 看起來是 OS 好像沒什麼差😂